These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marmé D. Cancer Res; 1996 May 15; 56(10):2299-301. PubMed ID: 8625303 [Abstract] [Full Text] [Related]
3. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720 [Abstract] [Full Text] [Related]
10. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD. Proc Natl Acad Sci U S A; 1997 Mar 18; 94(6):2156-61. PubMed ID: 9122164 [Abstract] [Full Text] [Related]
18. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Krieg M, Marti HH, Plate KH. Blood; 1998 Nov 01; 92(9):3388-93. PubMed ID: 9787178 [Abstract] [Full Text] [Related]
19. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. Masuda K, Ono M, Okamoto M, Morikawa W, Otsubo M, Migita T, Tsuneyoshi M, Okuda H, Shuin T, Naito S, Kuwano M. Int J Cancer; 2003 Jul 20; 105(6):803-10. PubMed ID: 12767066 [Abstract] [Full Text] [Related]